Key Highlights

  • Careteq (ASX:CTQ) shares were up 8.33% at $0.013 during the 22 October 2026 session, while the S&P/ASX 200 was down 0.64%.
  • In its FY26 results dated 27 August 2026, Careteq reported total Revenue and other income from continuing operations of $6.90 million and a net loss after tax of $0.40 million.
  • The company ended the year Debt free with $3.19 million cash at bank after selling Embedded Health Solutions for $5.0 million, less adjustments of about $1.0 million.

Careteq Limited (ASX:CTQ) shares were up 8.33% at $0.013 during the Trading session on 22 October 2026, based on data at 11:55 am. The S&P/ASX 200 stood at 8,774.90, down 0.64% (56.40 points), while the All Ordinaries stood at 8,897.80, down 0.66%. Careteq is a Melbourne-based clinical healthtech company that operates the HMR Referrals marketplace platform for home medicines reviews.

About the Company

Careteq Limited is listed on the Australian Securities Exchange under the code CTQ and has its office at Level 10, 99 Queen Street, Melbourne. It describes itself as an Australian healthtech company focused on solutions for the home care and disability sector.

Mark Simari is Executive Chairman. The ASX confirmed on 23 July 2026 that the company would continue to be quoted on the exchange following the divestment of its Embedded Health Solutions (EHS) business.

Business Overview

Following the EHS divestment, Careteq's operating focus centres on HMR Referrals, a fully owned marketplace platform that streamlines the process of completing Home Medicines Reviews (HMRs). The platform connects referral sources, general practitioners and accredited pharmacists.

The company's strategic plan for the platform covers GP clinic activation, pharmacist recruitment, scoping and building of artificial intelligence capability focused on process improvements, strategic collaborations with complementary industry partners, and scaling the platform to address unmet need in the home and aged care sector.

FY26 Financial Results

In its full year results dated 27 August 2026, covering the year ended 30 June 2026, Careteq reported total revenue and other income from continuing operations of $6.90 million, compared with $8.32 million in FY25. Revenue from contracts with customers was $6.08 million, down from $7.62 million. The company attributed the decline to only nine months of EHS revenue being recognised and to the write-back of previously accrued Research and Development (R&D) claim income.

EBITDA from continuing operations was $0.02 million, compared with $0.27 million a year earlier, and the net loss after tax from continuing operations was $0.40 million, compared with $0.07 million. The result includes a $2.02 million gain on the sale of EHS, partly offset by a $1.21 million write-back of R&D claim income linked to the delay in resolving a dispute with the Australian Taxation Office (ATO) over FY21 to FY23 claims.

Balance Sheet and Cost Base

EHS was sold to Nationwide Investments Holdings Pty Ltd for $5.0 million, less purchase price adjustments of about $1.0 million, resulting in cash consideration of about $4.0 million. The proceeds repaid vendor loans of approximately $2.47 million, including interest, that related to the 2024 Acquisition of the remaining 45% of EHS.

Careteq also completed a $2.2 million Capital raising and converted all convertible notes on issue into fully paid ordinary shares at $0.01 per share. At 30 June 2026 the company had cash at bank of $3.19 million, compared with $1.05 million a year earlier, no borrowings, compared with $2.25 million, and net Assets of $3.23 million, compared with $1.52 million. Annualised underlying corporate costs have been reduced to approximately $1.0 million.

Related Sector Context

Home medicines reviews form part of Australia's primary care and pharmacy services landscape, where digital platforms increasingly connect clinics, pharmacists and patients. Healthtech companies in this area are generally small and typically depend on platform adoption and referral volumes.

On the day of the data, the S&P/ASX 200 was down 0.64% and the All Ordinaries down 0.66% at 11:55 am, while Careteq's shares rose to $0.013 during the session.

Risks to Weigh In

Careteq's FY26 results show a net loss from continuing operations, and revenue declined from the prior year following the EHS sale. The ATO has issued amended assessments concerning historical R&D Tax Incentive claims for FY21 to FY23, and the company continues to progress a formal objection process, the outcome of which is uncertain.

The HMR Referrals strategy also depends on factors the company does not fully control, including GP clinic participation, pharmacist recruitment and the pace of platform scaling. Future acquisitions, which the company lists among its priorities, would carry integration and funding considerations of their own.

Catalysts on Watch

The company's stated near-term priorities for FY27 include executing the HMR Referrals strategic plan, activating GP clinics and expanding referral pathways, recruiting and engaging accredited pharmacists, and progressing AI-enabled workflow improvements.

Careteq also lists strategic collaborations, continued cost control, assessment of complementary acquisitions where strategically aligned, and progress on the ATO formal objection process. The results announcement did not specify dates for these milestones, so timing of progress remains to be seen.

Putting It Together

Careteq shares were higher at $0.013 during the session while the broader market declined. The company's FY26 results, dated 27 August 2026, describe a year of divestment, debt repayment and recapitalisation, with attention now on the HMR Referrals platform and the unresolved ATO matter.